Form 4: Arrowhead Pharmaceuticals Executive James C. Hamilton Reports Sale of 6,000 Shares

James C. Hamilton, Chief Discovery/Translational Medicine at Arrowhead Pharmaceuticals, sold 6,000 shares of common stock on April 1, 2024, at a weighted average price of $28.03.

Summary

• On April 1, 2024, James C. Hamilton, Chief Discovery/Translational Medicine at Arrowhead Pharmaceuticals, sold 6,000 shares of the company's common stock.
• The sale was executed at a weighted average price of $28.03 per share, with individual transactions ranging from $27.97 to $28.10.
• Following the transaction, Hamilton directly owns 204,851 shares of Arrowhead Pharmaceuticals, which includes shares underlying Restricted Stock Units subject to vesting conditions.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a stock sale by an executive. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their trading activities. The sale itself doesn't necessarily indicate a negative outlook for the company, as executives may sell shares for various personal financial reasons.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, although it is a common occurrence.

Key Dates